Xencor slides on underwhelming prostate cancer data for vudalimab bispecific

2024-02-28

临床结果免疫疗法临床2期抗体药物偶联物

Shares of Xencor fell as much as 16% on Wednesday after the company reported what investors saw as lacklustre efficacy results from a Phase II trial of its XmAb bispecific antibody vudalimab, which targets immune checkpoint receptors PD-1 and CTLA-4.

Analysts at BMO Capital Markets said the study evaluating vudalimab monotherapy in 14 high-risk metastatic castration-resistant prostate cancer (mCRPC) patients was nevertheless "encouraging" on efficacy given the heavily-pretreated population. The cohort underwent a median four prior lines of therapy, most of whom had received chemotherapy, while 29% had received prior therapy with Novartis' radioligand therapy Pluvicto (lutetium Lu 177 vipivotide tetraxetan).

Out of 12 evaluable patients, Xencor said vudalimab achieved an objective response rate (ORR) of 33% (4/12), but with only three confirmed partial responses. A quarter of evaluable patients showed PSA marker reductions exceeding 90% from their baseline levels (PSA90).

While investors appeared underwhelmed, BMO analysts noted that these results stack up favourably against competing treatments where ORRs have ranged from roughly 11% to 26% and PSA90 rates have hovered around 10% to 26%.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构